BioSpace News Archive

Genocea Biosciences, Inc. (NASDAQ: GNCA), presents updated immunogenicity and clinical response data from the GEN-009 Phase 1 trial that continue to validate the company’s unique and differentiated approach to identifying clinically meaningful immunotherapy targets through the proprietary ATLAS selection process

100% (12/12) of patients with relapsed and refractory multiple myeloma treated with Arcellx’s BCMA-specific CAR-modified T-cell therapy achieved responses per IMWG criteria

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-022-05 prospectively designed study on a retrospective TCGA cohort.

Achilles Therapeutics plc (NASDAQ: ACHL), today presented a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, which is being held in a virtual format from June 4-8, 2021.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant

CollPlant, a regenerative and aesthetic medicine company, announced the uplisting of its ordinary shares to the Nasdaq Global Select Market® effective at the open of market, Friday, June 4, 2021.

Ortho Regenerative Technologies Inc., a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced that it has received a clinical hold letter from the U.S.

WELL Health Technologies Corp. a company focused on consolidating and modernizing clinical and digital assets within the primary healthcare sector, is pleased to announce that Hamed Shahbazi , WELL’s Chairman and CEO, will be participating in the following upcoming virtual conference

EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently available in all 50 states, including eight states with high rates of two variants of concern

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan.